Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Folate as a potential treatment for lethal ventricular arrhythmias in TANGO2-deficiency disorder
Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, Lilei Zhang
Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, Lilei Zhang
View: Text | PDF
Research Article Cardiology Genetics

Folate as a potential treatment for lethal ventricular arrhythmias in TANGO2-deficiency disorder

  • Text
  • PDF
Abstract

TANGO2-deficiency disorder (TDD) is an autosomal-recessive genetic disease caused by biallelic loss-of-function variants in the TANGO2 gene. TDD-associated cardiac arrhythmias are recalcitrant to standard antiarrhythmic medications and constitute the leading cause of death. Disease modeling for TDD has been primarily carried out using human dermal fibroblast and, more recently, in Drosophila by multiple research groups. No human cardiomyocyte system has been reported, which greatly hinders the investigation and understanding of TDD-associated arrhythmias. Here, we established potentially novel patient-derived induced pluripotent stem cell differentiated cardiomyocyte (iPSC-CM) models that recapitulate key electrophysiological abnormalities in TDD. These electrophysiological abnormalities were rescued in iPSC-CMs with either adenoviral expression of WT-TANGO2 or correction of the pathogenic variant using CRISPR editing. Our natural history study in patients with TDD suggests that the intake of multivitamin/B complex greatly diminished the risk of cardiac crises in patients with TDD. In agreement with the clinical findings, we demonstrated that high-dose folate (vitamin B9) virtually abolishes arrhythmias in TDD iPSC-CMs and that folate’s effect was blocked by the dihydrofolate reductase inhibitor methotrexate, supporting the need for intracellular folate to mediate antiarrhythmic effects. In summary, data from TDD iPSC-CM models together with clinical observations support the use of B vitamins to mitigate cardiac crises in patients with TDD, providing potentially life-saving treatment strategies during life-threatening events.

Authors

Weiyi Xu, Yingqiong Cao, Sara B. Stephens, Maria Jose Arredondo, Yifan Chen, William Perez, Liang Sun, Andy C. Yu, Jean J. Kim, Seema R. Lalani, Na Li, Frank T. Horrigan, Francisco Altamirano, Xander H.T. Wehrens, Christina Y. Miyake, Lilei Zhang

×

Figure 5

Folate ameliorated arrhythmias in TDD iPSC-CMs.

Options: View larger image (or click on image) Download as PowerPoint
Folate ameliorated arrhythmias in TDD iPSC-CMs.
(A) Representative field...
(A) Representative field potential recordings of TAN016+Ad-GFP (top row) or TAN002 (bottom row) with vehicle (left), 100 mg/L folate (middle), or folate with 1 mM MTX (right) for 12 hours. In the MTX+folate group, cells were pretreated with 1 mM MTX for 24 hours before applying folate. Asterisk indicates ED. (B) ED frequency of TAN016+Ad-GFP with vehicle, folate, or folate with MTX (Folate+MTX) (n = 4–6). *P < 0.05 versus vehicle. (C) Beating rate of TAN016+Ad-GFP with vehicle, folate, or folate+MTX (n = 4–6). *P < 0.05 versus vehicle. (D) FPD (left panel) and cFPD (right panel) of TAN016+Ad-GFP with vehicle, folate, or folate+MTX (n = 4–6). (E) ED frequency in TAN002 with vehicle, folate, or folate+MTX (n = 7–43). *P < 0.05 versus vehicle. (F) Beating rate of TAN002 and TAN002c vehicle, folate, or folate+MTX (n = 7–43). *P < 0.05 versus 0 hours. (G) FPD (left panel) and cFPD (right panel) of TAN002 and TAN002c with vehicle, folate, or folate+MTX (n = 7–11). Statistical difference was determined by 2-way ANOVA corrected by Šidák method (α = 0.05). Data are mean ± SEM. Error bars smaller than the symbol size are not shown.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts